JOURNAL REVIEWED: Ocular Immunology and Inflammation | Retina | Acta Ophthalmologica
Latest Contribution
Type 3 CNV and anti-VEGF
The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...
OCTA and pigment epithelium detachments
Yannuzzi et al. report on their study aiming to evaluate the ability of optical coherence tomography angiography (OCTA) to differentiate vascularised from nonvascularised pigment epithelium detachments (PEDs) using conventional imaging techniques, including fundus fluorescein angiography (FFA) and indocyanine green (ICG),...
Macular atrophy with aflibercept
The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...
